Feature | October 14, 2011| Dave Fornell

FDA Panel Gives Unanimous Nod to Cook Medical’s Zilver PTX Drug-Eluting Stent

October 14, 2011 – A U.S. Food and Drug Administration (FDA) review panel gave its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts to go before FDA review. It is the first drug-eluting stent (DES) for peripheral leg vessels, the first self-expanding DES and the first DES that does not use a polymer to load and elute its drug.

All 11 members of the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted Oct. 13 in favor of  Cook Medical's device on the basis of its safety, efficacy and acceptable risk profile. The recommendation is the latest step in the regulatory review process that the company hopes will ultimately lead to FDA approval to sell the Zilver PTX stent in the United States.

“Cook Medical is very pleased that the FDA’s Circulatory System Devices Panel has recognized the merits of Zilver PTX, and we look forward to a final decision on approval to market this device in the U.S. from the FDA in the coming months,” said Rob Lyles, vice president and global leader of Cook Medical’s peripheral intervention unit. “Cook Medical is dedicated to continually innovating and delivering medical devices that improve the quality of patient care worldwide, and we wholeheartedly feel Zilver PTX provides a great example of that patient-focused business philosophy.”

The FDA is not bound by decisions made by its panels, but usually follows their recommendations. Final FDA review will likely take place by the end of the year, or the beginning of 2012.

Following CE mark approval in 2009, Cook Medical’s Zilver PTX DES is now available for sale in 48 countries around the world including the United Kingdom, Germany, France, Brazil, New Zealand and Taiwan.

The stent is seen by many experts as a major step forward in treatment options for patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA). Occlusions in the SFA are difficult to treat and frequently re-occlude.

Zilver PTX is made of nitinol, a shape memory metal alloy that will spring back into its original shape under axial, torsional and bending flexibility. Self-expanding stents are used in the SFA because of the need to torque and compress with the vessel.

The addition of the anti-tissue proliferation drug paclitaxel on the Zilver stent has shown promising results in clinical trials in lowering the usually high restenosis rates of SFA lesions.

Polymers used to load drugs and control drug elution on DES have been implicated as the culprit in late-stent thrombosis sometimes seen in coronary stents. Vendors have been researching ways to eliminate polymers, allowing DES to become a bare metal stent following full drug elution into the vessel wall. The Zilver PTX would be the first DES in the United States not to use polymer, which is seen by many interventional experts as the way of the future.

For more information: www.cookmedical.com

Related Content

TOBA-BTK study, twelve-month results, SCAI 2016, Tack Endovascular System, critical limb ischemia
News | Peripheral Arterial Disease (PAD)| May 05, 2016
Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-...
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
STEMI, delayed or deferred stent implantation, DANAMI-3-DEFER trial, ACC.16
News | Cath Lab| April 18, 2016
Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest...
ACR, American College of Radiology, MEDCAC, peripheral arterial disease, PAD, seniors
News | Peripheral Arterial Disease (PAD)| April 18, 2016
The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral...
Absorb, bioresorbable stents
Feature | Stents Bioresorbable| April 13, 2016 | Dave Fornell
Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings ov
Sponsored Content | Videos | Stents Bioresorbable| April 12, 2016
Gregg Stone, M.D., director of cardiovascular research and education at Columbia University Medical Center / New York
Corindus, CorPath Robotic System, FDA clearance, peripheral vascular interventions
Technology | Robotic Systems| March 29, 2016
Corindus Vascular Robotics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the CorPath...
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter| March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
Medinol, NIRTRAKS Study, NIRxcell Stent System, first patient

Image courtesy of Medinol

News | Stents| March 24, 2016
March 24, 2016 — Medinol announced the enrollment of their first patient in the U.S. NIRTRAKS Study.
Overlay Init